Dichlorobenzyl Alcohol: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: April 15, 2026🚩 Report this page

Dichlorobenzyl Alcohol

Antiseptics

Sold as CEPACOL SENSATIONS · CEPACOL SENSATIONS COOL… · CEPACOL CHILDREN'S FRUITY… · CEPACOL SENSATIONS SORE…

GB MHRACA Health Canada

Drug class: Antiseptics
Availability: See label
Routes: Oral
Markets covered: 2
Products on record: 7

Overview

Dichlorobenzyl Alcohol is an active pharmaceutical ingredient in the Antiseptics group (R02AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	March 13, 2026
CA Canada	Health Canada	6	April 15, 2026

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised March 13, 2026[1]

Relief of symptoms of sore throat in adults and adolescents over 12 years of age.

How to take

GBOfficial regulatory label

CACanada· Health Canada

6 products

6 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].

Brands in Canada (4)

Sources & citations

[1]MHRA (UK) · PL182590010 · revised March 13, 2026
[2]Health Canada (DPD) · 02375567 · revised March 22, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised March 13, 2026[1]

During the period of use, the following adverse reactions have been reported for the combination of active substances in this medicinal product: During treatment of chronic conditions and with long-term use additional side effects may occur.
The adverse reactions associated with the combination of active substances in this medicinal product are described below by system organ class and ranked according to frequency: very common (≥ 1/10), common (≥ 1/100, < 1/10), uncommon (≥ 1/1,000, < 1/100), rare (≥1/10,000, < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data) System Organ Class Frequency Adverse events Immune system disorders Rare Hypersensitivity reactions1 (burning, itching), angioedema, urticaria, bronchospasm, hypotension, stinging of the throat and unpleasant taste Respiratory, thoracic and mediastinal disorders Not known Pharyngeal edema Gastrointestinal disorders Not known Nausea, oral discomfort, swelling of the mouth, dysgeusia.
Skin and subcutaneous tissue disorders Not known Rash Description of Selected Adverse Reactions 1 Hypersensitivity reactions to lidocaine may present in the form of angioedema, urticaria, bronchospasms and hypotension with syncope.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised March 13, 2026[1]

If symptoms do not improve or become worse after 2 days, contact a doctor or pharmacist. Follow the indicated dosage: when taken in large amounts or repeatedly, this medicine may impact the nervous system as it passes through the bloodstream, possibly causing convulsions or affecting the heart.
The prolonged use of this medicine for more than 5 days is not recommended, as it may alter the natural microbial balance of the throat. If symptoms persist for longer than 2 days, get worsen or if other symptoms appear, such as high fever, headache, nausea or vomiting, and skin rash, the clinical condition should be evaluated for bacterial infections (angina, tonsillitis).
It should be administered with caution in acutely ill or frail elderly patients, as they are more sensitive to adverse reactions to this medicinal product. In susceptible patients, due to the local anaesthetic effect, the risk of choking may increase, or the sensitivity of the mouth or throat may temporarily be modified.
This medicine should not be used in the area of mouth and throat if greater acute wounds exist. The anaesthesia of the throat caused by this medicinal product may lead to pulmonary aspiration (coughing while eating, giving the impression that the person is choking).
It is therefore imperative not to take this medicine before meals or drinking. 016 g of glucose per lozenge, which should be considered when treating patients with glucose-galactose malabsorption and patients with diabetes mellitus.
Chloralieve Mint Flavour lozenges contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase- isomaltase insufficiency should not take this medicine. 495 g of sucrose per lozenge, which should be considered when treating patients with glucose-galactose malabsorption and patients with diabetes mellitus.
Chloralieve Mint Flavour lozenges contains terpenes found in levomenthol. Excessive doses of terpenes have been associated with neurological complications such as convulsions in children. Chloralieve Mint Flavour lozenges may cause numbness of the tongue and may increase the danger of biting trauma.
Therefore care should be taken in eating and drinking hot foods. The patient should be aware that the production of topical anesthesia may impair swallowing and thus enhance the danger of aspiration. For this reason, food should not be ingested directly following use of local anesthetic preparations in the mouth or throat area.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

CACanada· Health Canada

Drugs in the same class

Sources & citations